IMUNON to present new data on ovarian cancer therapy at AACR conference

LAWRENCEVILLE, N.J. - IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company with a current market capitalization of $12.86 million, will present new translational data from its Phase 2 OVATION 2 Study of IMNN-001 at the American Association for Cancer Research Special Conference on Advances in Ovarian Cancer Research, taking place September 19-21, 2025, in Denver. According to InvestingPro analysis, the company maintains a positive cash position despite aggressive R&D investments, though it’s currently experiencing rapid cash burn.

IMNN-001 is an interleukin-12 DNA plasmid vector incorporated into a nanoparticle delivery system that enables local production of IL-12 protein in the tumor microenvironment. The therapy is designed to induce anti-cancer immunity by promoting T-lymphocyte and natural killer cell proliferation.

The presentation, titled "IMNN-001, an IL-12 gene therapy, added to Neo/Adjuvant chemotherapy safely turns the tumor microenvironment cold-to-hot in newly diagnosed epithelial ovarian cancer," will be delivered by Douglas V. Faller, Chief Medical Officer at IMUNON, on September 20.

The company is currently conducting the OVATION 3 pivotal Phase 3 trial of IMNN-001 in women with advanced epithelial ovarian cancer. This study follows Phase 2 results that showed a median 13-month increase in overall survival and a 3-month increase in progression-free survival compared to standard care alone. With the stock trading near its 52-week low of $4.83, InvestingPro subscribers can access 14 additional key insights about IMUNON’s financial health and market position through comprehensive Pro Research Reports, available for over 1,400 US stocks.

The Phase 2 data also indicated enhanced outcomes when IMNN-001 was combined with poly ADP-ribose polymerase inhibitors as maintenance therapy. In this subgroup, median overall survival has not yet been reached as patients surpass five years since randomization, compared to 37 months with standard care.

OVATION 3 is currently enrolling patients at four trial sites, with up to 46 additional sites being considered for activation, according to the company’s press release statement. The stock has seen significant volatility, with a 63.46% decline over the past year, reflecting the inherent risks in clinical-stage biotech investments.

In other recent news, Imunon Inc. reported its second-quarter earnings for 2025, revealing a significant earnings per share (EPS) miss compared to analysts’ forecasts. The company posted an EPS of -$2.15, which was substantially lower than the expected -$0.32, resulting in a surprise of 571.88%. This considerable deviation from expectations highlights the challenges Imunon faced during the quarter. The earnings report did not meet investor expectations, leading to concerns about the company’s financial performance. Analysts and investors are closely monitoring these developments, given the substantial difference between the forecasted and actual EPS figures. These recent developments underscore the importance of closely watching Imunon’s future earnings reports for any signs of financial recovery or further challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.